Auven Therapeutics Mergers and Acquisitions Summary

Private Equity Firm Profile

Auven Therapeutics’ most common sector for investment islife science (100%). The Firm’s most common investment types include venture (60%) and buyout (lbo, mbo, mbi) (20%). In total, Auven Therapeutics has invested in 2 US states and 3 different countries.

The Firm’s most common exit type is trade sale (75%). Auven Therapeutics’ largest (disclosed) exit occurred in 2015 when it sold Sprout Pharmaceuticals for $1.0B.

Join Mergr to view Auven Therapeutics’ full profile and discover more small private equity firm investors just like it.

M&A Summary

  • M&A Total Activity9
    • M&A Buy Activity5
    • M&A Sell Activity4
  • Total Sectors Invested 1
  • Total Countries Invested 3
  • M&A Buy/Sell Connections 3
  • M&A Advisors 2

Auven Therapeutics

Auven Therapeutics

6501 Redhook Plaza, Suite 201,
St. Thomas, 00802
Virgin Islands (U.S.)
(340) 779-6908
www.auventx.com
info@auventx.com

Auven Therapeutics is a private equity firm focused on investing in life science companies. Auven looks to acquire controlling ownership in promising therapeutic products or platforms and develop programs to selling them as clinically and commercially validated products to established pharmaceutical companies. Auven Therapeutics was established in 2007 and is headquartered in St. Thomas, US Virgin Islands.


Investment Criteria

Sectors of Interest: Life Science

Target Transaction Types: Buyout (LBO, MBO, MBI), Growth Capital

Geographic Preferences: East US, Midwest US, South US, West US, Western Europe

Transaction Criteria Min Max
Target Revenue - -
Target EBITDA - -
Investment Size - -
Enterprise Value - -

M&A Summary

Buy vs Sell

Year ≤ '19 '20 '21 '22 '23 '24 T
Buy (0.0/yr) # 5 - - - - - 5
Sell (0.2/yr) # 3 1 - - - - 4
vol $1.3B $1.3B
  9

Most Recent M&A

Company Date Value Type
ADC Therapeutics SA 2020-05-11 - IPO
Epalinges, Switzerland · www.adctherapeutics.com
Ocular Technologies Sarl 2016-10-26 40M USD Trade Sale
Lyme Park, South Africa · www.oculartechnologies.com
Sprout Pharmaceuticals, Inc. 2015-08-20 1.0B USD Trade Sale
Raleigh, North Carolina · www.sproutpharma.com
Spirogen Ltd. 2013-10-15 240M USD Trade Sale
London, United Kingdom · www.spirogen.com
ADC Therapeutics SA 2013-10-15 - Growth Capital
Epalinges, Switzerland · www.adctherapeutics.com
ADC Products 2013-10-01 - Buyout (LBO, MBO, MBI)
, Switzerland
Sprout Pharmaceuticals, Inc. 2012-03-01 - Venture
Raleigh, North Carolina · www.sproutpharma.com
Kolltan Pharmaceuticals, Inc. 2010-01-19 - Venture
New Haven, Connecticut · www.kolltan.com
Spirogen Ltd. 2009-01-01 - Venture
London, United Kingdom · www.spirogen.com
View All >>

M&A by Sector

Sector Current # Value All-time # Value
Life Science 1 (100%) - 5 (100%) -
Total 1 - 5 -

Acquisitions By Geo

State/Country Current # Value All-time # Value
Switzerland 1 (100%) - 2 (40%) -
United States - - 2 (40%) -
  North Carolina - - 1 (20%) -
  Connecticut - - 1 (20%) -
United Kingdom - - 1 (20%) -
Total 1 - 5 -

Acquisitions by Deal Type

Type Current # Value All-time # Value
Venture - - 3 (60%) -
Buyout (LBO, MBO, MBI) 1 (100%) - 1 (20%) -
Growth Capital - - 1 (20%) -
Total 1 - 5 -

Exits by Deal Type

Type Total # Value
Trade Sale 2 (50%) 1.2B (97%)
Trade Sale - Public Company 1 (25%) 40M (3%)
IPO 1 (25%) -
Total 4 $1.3B

Top M&A Advisors

Financial Deals
MTS Health Partners LP
 1
Legal Deals
Akin Gump Strauss Hauer & Feld
 1

Deal Values

sell # Total
> $1B 1 $1.0B
$100M to $1B 1 $240M
< $100M 1 $40M
TOTAL $1.3B
Largest Sprout Pharmaceuticals, Inc.
$1.0B (2015-08-20)

M&A Connections

Deals
Exited to
Strategic(s)
75%
3 (75%)

Investor Summary

Investor Type

Private Equity Firm

Size

Small

Established

2007

Specialist/Generalist

Specialist

Leadership

Peter Corr

Co-Founder & Managing General Partner

Stephen Evans-Freke

Co-Founder & Managing General Partner

Jim Cooper

CIO

Patrick O'Connor

Managing Director

Tomasz Sablinski

Managing Director & Head of Clinical Development

FAQ

When was Auven Therapeutics founded?

Auven Therapeutics was founded in 2007.

What type of investor is Auven Therapeutics?

Auven Therapeutics is a private equity firm.

Where is Auven Therapeutics headquartered?

Auven Therapeutics is headquartered in St. Thomas, Virgin Islands (U.S.).

 Subscribe to unlock this and 209,180
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More
1 Week Free Trial Learn More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB

Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 202K M&A Transactions
  • 205K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 81K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.

Mergr

Product

Company

Legal